| Ping Qiu,Gang Chen,Yuhong Dai,Hong Qiu. Establishment and characterization of an oxaliplatin-resistant hepatic cancer cell line. Oncol Transl Med, 2018, 4: 48-53. |
| Establishment and characterization of an oxaliplatin-resistant hepatic cancer cell line |
| Received:April 06, 2018 Revised:May 17, 2018 |
| View Full Text View/Add Comment Download reader |
| KeyWord:hepatocellular carcinoma (HCC); multidrug resistance (MDR); excision repair-cross complementing 1 (ERCC1); oxaliplatin |
| Author Name | Affiliation | E-mail | | Ping Qiu | Oncology Department,Jingzhou Central Hospital | tjqiuhong@163.com | | Gang Chen | Integration Traditional Chinese Medicine and Weste,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Yuhong Dai | Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Hong Qiu | Department of Oncology，Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | |
|
| Hits: 6426 |
| Download times: 7462 |
| Abstract: |
| Objective?The aim of the current study was to establish an oxaliplatin-resistant hepatoma cell line (HepG2/OXA) and investigate the potential mechanisms of its drug resistance.
Methods?The hepatoma cell subline, HepG2/OXA, resistant to oxaliplatin (OXA), was established from a parent cell line HepG2, by stepwise exposure to gradually increasing concentrations of OXA over a half-year period. Chemosenstivity of the cytotoxic drugs, OXA, cisplatin (CDDP), adriamycin (ADM), and 5-fuorouracil (5-FU), was determined in HepG2 and HepG2/OXA cells, by the Cell counting kit-8 (CCK8) assay. Cell cycle distribution of HepG2 and HepG2/OXA cells was analyzed by Flow cytometry (FCM). The expression levels of several drug resistance-related proteins, such as P-glycoprotein (P-gp), multidrug resistant protein 1 (MRP1), and excision repair-cross complementing 1 (ERCC1) protein in the two cell lines were tested by the western blot assay.
Results?The IC50 of OXA in HepG2/OXA and HepG2 were 136.84 μmol/L and 23.86 μmol/L, respectively. The resistance index (RI) was 5.34. HepG2 was also demonstrated to be cross-resistant to other anti-tumor agents, such as 5-FU, ADM, and CDDP. The percentage of HepG2/OXA cells in the S phase was significantly decreased compared to HepG2 cells (25.58% ± 2.36% vs 14.37% ± 2.54%, P < 0.05), while the percentage of cells in the G0/G1 and G2/M phases showed no statistical difference (respectively 55.29% ± 4.98% vs 56.73% ± 4.56%, P > 0.05, and 24.63% ± 4.81% vs 28.26% ± 3.82%, P > 0.05). The ERCC1 was found to be over expressed in HepG2/OXA cells, while there was no difference in the expressions of P-gp and MRP1 between the multiple drug resistance (MDR) phenotype cell line and its parental cell line.
Conclusion?HepG2/OXA showed an MDR ability; the over expression of ERCC1 might be associated with the platinum resistance of the cells, but P-gp and MRP1 are not.
|
| Close |
|
|
|